Myths About CJC-1295

A whole mythology has formed around CJC-1295: from promises of "rejuvenation without side effects" to the conviction that it is "almost a vitamin." Most of these claims have never been tested in studies or contradict what is known from scientific publications. The editorial team has gathered the most common myths and compared them with the facts.

Myth 1: "It is a natural substance, so it is safe"

Supporters of CJC-1295 often stress that it "merely nudges your own pituitary," and therefore acts naturally. This is partly true: the drug does indeed stimulate the receptor of growth-hormone-releasing hormone (GHRH) rather than replacing growth hormone from outside. However, it does not follow from this that the effect is physiological.

CJC-1295 is a synthetic molecule that does not exist in the human body. It contains four amino acid substitutions compared with the natural GHRH fragment and a chemical linker that covalently binds to albumin. Natural GHRH lives in the blood for mere minutes, while CJC-1295 with DAC lasts for days. It is precisely this prolonged stimulation that is fundamentally non-physiological.

In early studies in healthy adults, a single injection raised growth hormone levels several-fold for six or more days, and IGF-1 levels for more than a week. For a body accustomed to short nighttime pulses of GH, this is a substantially different hormonal regime.

Moreover, the "naturalness" of the mechanism does not guarantee safe consequences. An excess of one's own growth hormone - for example, in acromegaly - is a serious disease, even though the hormone in it is entirely "one's own." Safety is determined by dose, duration, and control, not by the origin of the signal.

Myth 2: "With DAC or without - it's the same thing"

Two different substances are sold on the gray market under similar names. The original CJC-1295, developed by the company ConjuChem, contains the DAC (Drug Affinity Complex) component - a linker for binding to albumin. It was precisely this molecule that was studied in the published clinical trials of 2006.

"CJC-1295 without DAC" is essentially a modified GHRH(1-29), also called Mod GRF (1-29). It is more resistant to enzymes than the natural hormone but does not bind to albumin and is eliminated in a much shorter time. There are practically no published clinical studies on this substance.

So it is incorrect to transfer conclusions from studies of one molecule to another. When advertising for "CJC-1295 without DAC" refers to studies by Teichman or Ionescu, this is a substitution: those works concerned a different substance with fundamentally different pharmacokinetics.

The confusion is compounded by the fact that sellers do not always honestly indicate what exactly is in the vial. Without an independent laboratory analysis, a buyer cannot know which substance and in what quantity they received.

Myth 3: "It is a legal, registered drug"

CJC-1295 is not registered as a medicinal product by the FDA, by the European Medicines Agency, or, as far as the editorial team knows, by the regulators of other major countries. Clinical development stopped at early stages and did not reach phase III.

The "for research only" label on the packaging does not make the product a legal medicine - on the contrary, it directly indicates that the substance is not intended for human use. Such products do not undergo pharmaceutical quality, sterility, and stability control.

In the USA, in the 2020s, the FDA classified CJC-1295 among the substances for which there are significant safety concerns when used in pharmacy compounding. For athletes the status is unambiguous: WADA prohibits GHRH and its analogs in class S2, and CJC-1295 is listed in the Prohibited List as an example.

The legal status of circulation differs among countries and changes, so the editorial team does not give legal advice. But the medical fact is unchanged: there are no official indications for the use of CJC-1295.

Myth 4: "It burns fat and builds muscle like growth hormone"

The logic of the myth is simple: if CJC-1295 raises GH, then it will give all the effects of GH. However, the published studies of CJC-1295 evaluated hormone levels, not body composition, strength, or athletic performance. There is no data in the peer-reviewed literature that the substance increases muscle mass or strength in humans.

Even regarding growth hormone itself the picture is more modest than people are used to thinking. The systematic review by Liu and co-authors (Annals of Internal Medicine, 2008) on the effect of GH on athletic performance in healthy people showed that it increases lean mass, but a significant part of the gain may be fluid, and an improvement in strength and endurance was not proven.

The only GHRH analog with a proven effect on body composition is tesamorelin, which reduces visceral fat in patients with HIV-associated lipodystrophy. But this is a specific population, a specific drug, and a moderate effect that disappears after discontinuation. There are no grounds to transfer these results to CJC-1295 in healthy athletes.

Myth 5: "No side effects whatsoever"

In early studies of CJC-1295, injection-site reactions, headache, flushing, and a feeling of heat were described - mostly mild and transient. But short trials with a small number of participants are not able to detect rare or delayed complications.

The biologically expected risks of substances that persistently raise GH and IGF-1 are well known from the experience of growth hormone therapy and from the clinic of acromegaly:

• fluid retention, edema, joint pain, carpal tunnel syndrome;
• reduced insulin sensitivity and elevated glucose;
• a theoretical effect on the growth of existing neoplasms via IGF-1;
• formation of antibodies to the peptide and hypersensitivity reactions;
• risks associated with non-sterility and impurities in unregistered products.

Separately, we will mention that the clinical study of CJC-1295 in 2006 was stopped after the death of one of the participants. The company reported that a connection with the drug had not been established, but this episode well illustrates how incomplete the safety data on the substance are.

The claim of "no side effects" actually means only one thing: "no one has systematically looked." An absence of data and proven safety are different things.

Editorial conclusions

Most popular claims about CJC-1295 rest not on studies but on extrapolation: "if it raises GH, then it acts like GH." The scientific data confirm only the pharmacological effect - a rise in GH and IGF-1.

The "with DAC" and "without DAC" molecules are different substances, and data about one cannot be transferred to the other.

The drug has no official indications, is not registered by major regulators, and is banned in sport; there is no data on long-term safety.

For a deeper understanding of the topic we recommend "The History of the Discovery of CJC-1295," "Medical Use of CJC-1295: Official Indications," and "Myths About Tesamorelin."

References

1. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805.
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797.
3. Liu H, Bravata DM, Olkin I, et al. Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med. 2008;148(10):747–758.
4. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370.
5. Møller N, Jørgensen JOL. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152–177.
6. World Anti-Doping Agency. Prohibited List. Montreal: WADA; чинна редакція.